SPOSETTI, CATERINA
SPOSETTI, CATERINA
Universita' degli Studi di MILANO
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study
2024 A. Botticelli, R. Caputo, S. Scagnoli, S. Pisegna, M. De Laurentiis, G. Curigliano, M. Lambertini, F. Pantano, A. Palazzo, I. Paris, C. Vernieri, B. Tedesco, M. Giampaglia, M. Palleschi, Z. Ballatore, D. Alesini, G. D'Auria, A. Fabbri, L. Rossi, A. Verrazzo, R. Scafetta, D. Marinelli, C. Sposetti, V. Barberi, L. Strigari, P. Marchetti, D. Santini, A. Fabi
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial
2024 F. Ligorio, R. Lobefaro, G. Fucà, L. Provenzano, L. Zanenga, V. Nasca, C. Sposetti, G. Salvadori, A. Ficchì, A. Franza, A. Martinetti, E. Sottotetti, B. Formisano, C. Depretto, G. Scaperrotta, A. Belfiore, A. Vingiani, C. Ferraris, G. Pruneri, F. de Braud, C. Vernieri
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
2023 S. Morganti, S. Gandini, E. Nicolo, E. Zattarin, C. Corti, A. Verrazzo, P.P.M.B. Giachetti, C. Sposetti, M.G. Razeti, B.T. Salimbeni, L. Boldrini, A.C. Schianca, R. Caputo, C. Vernieri, E. Munzone, M. Lambertini, M. De Laurentiis, G. Viale, G. Curigliano, C. Criscitiello
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
2023 L. Provenzano, R. Lobefaro, F. Ligorio, E. Zattarin, L. Zambelli, C. Sposetti, D. Presti, G. Montelatici, A. Ficchì, A. Martinetti, A. Arata, M. Del Vecchio, C. Lauria Pantano, B. Formisano, G.V. Bianchi, G. Capri, F. de Braud, C. Vernieri, G. Fucà
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments
2023 C. Valenza, D. Trapani, S. Gandini, C. Sposetti, L. Boscolo Bielo, A. Marra, T. Giarratano, D. Favero, L. Cortesi, L. Moscetti, M. Pistelli, R. Berardi, A. Zambelli, M. Lambertini, L. Del Mastro, V. Guarneri, C. Vernieri, G. Curigliano
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023 E. Zattarin, D. Presti, L. Mariani, C. Sposetti, R. Leporati, A. Menichetti, C. Corti, C. Benvenuti, G. Fucà, R. Lobefaro, F. Ligorio, L. Provenzano, A. Vingiani, M. Del Vecchio, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, A. Esposito, C.A. Giorgi, L. Lalli, L. Boldrini, P.P.B. Giacchetti, A.C. Schianca, V. Guarneri, R. Pedersini, A. Losurdo, A. Zambelli, D. Generali, C. Criscitiello, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities
2023 E. Zattarin, I. Taglialatela, R. Lobefaro, R. Leporati, G. Fucà, F. Ligorio, C. Sposetti, L. Provenzano, J. Azzollini, A. Vingiani, C. Ferraris, G. Martelli, S. Manoukian, G. Pruneri, F. de Braud, C. Vernieri
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
2023 E. Zattarin, L. Mariani, A. Menichetti, R. Leporati, L. Provenzano, F. Ligorio, G. Fucà, R. Lobefaro, L. Lalli, A. Vingiani, F. Nichetti, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, C. Corti, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, D. Presti, C. Sposetti, C.A. Giorgi, V. Guarneri, R. Pedersini, A. Losurdo, D. Generali, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study
2022 M. Niger, F. Nichetti, A. Casadei-Gardini, M.D. Rizzato, C. Pircher, M. Bini, A. Franza, M. Rimini, V. Burgio, C. Sposetti, L. Fornaro, I.G. Rapposelli, F.E. D'Amico, G. Aprile, C. Vivaldi, G.L. Frassineti, M. Milione, G. Leoncini, A. Cappetta, E. Vasile, M. Fassan, F. Morano, F. Perrone, E. Tamborini, G. Pruneri, S. Lonardi, V. Mazzaferro, F. Pietrantonio, M. Di Bartolomeo, F. de Braud